None listed
Conditions
Brief summary
The mineral magnesium has been shown to be safe and effective in the treatment of severe asthma when given intravenously (directly into the blood); however, only limited research has been conducted to find out the effect of magnesium given via nebuliser so that it can be inhaled by patients with severe exacerbations of asthma. A nebuliser is a machine that turns liquid medication into vapour so that it can be inhaled (breathed in). It is thought that giving the magnesium by the nebuliser might reduce the risk of side effects compared with giving it intravenously. In this study the magnesium will be given using a nebuliser along with a medication called salbutamol which is commonly used to treat asthma. The study will compare the effectiveness and safety of giving magnesium this way with giving the standard treatment of salbutamol alone in people having a severe asthma attack.
Interventions
The treatment intervention is 2.5mL of 0.25mmol/mL magnesium sulphate solution given as a nebulised inhalation on 3 occasions, at time (T) = 0min, T = 30min and T = 60min.
Sponsors
Medical Research Institute of New Zealand
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Aged between 16 and 65 years; Doctor diagnosis of asthma; Presentation to the Emergency Department (ED) with a severe exacerbation of asthma (initial FEV1 < or = 50% predicted)
Exclusion criteria
Patients requiring intubation or too unwell to perform spirometry on at presentation; Known cardiac disease, chronic renal insufficiency or another serious medical condition that would prevent their participation in the trial; Pregnant women; Pneumothorax or pneumonia; Previously documented chronic airflow limitation with fixed airways obstruction.
Outcome results
None listed